BR112015007870A2 - combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com um inibidor de mek - Google Patents

combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com um inibidor de mek

Info

Publication number
BR112015007870A2
BR112015007870A2 BR112015007870A BR112015007870A BR112015007870A2 BR 112015007870 A2 BR112015007870 A2 BR 112015007870A2 BR 112015007870 A BR112015007870 A BR 112015007870A BR 112015007870 A BR112015007870 A BR 112015007870A BR 112015007870 A2 BR112015007870 A2 BR 112015007870A2
Authority
BR
Brazil
Prior art keywords
oxo
combination
mek inhibitor
anticancer activity
derivative
Prior art date
Application number
BR112015007870A
Other languages
English (en)
Other versions
BR112015007870B1 (pt
Inventor
Bladt Friedhelm
Friese-Hamim Manja
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112015007870A2 publication Critical patent/BR112015007870A2/pt
Publication of BR112015007870B1 publication Critical patent/BR112015007870B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)

Abstract

resumo patente de invenção: "combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com um inibidor de mek". a presente invenção refere-se a uma composição farmacêutica que compreende: 3-(1-{3-[5-(1-metil-piperidin-4-ilmetóxi)-pirimidin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila ou um sal farmaceuticamente aceitável e/ou solvato do mesmo e n-((s)-2,3-di-hidróxi-propil)-3-(2-flúor-4-iodo-fenilamino)-isonicotinamida ou um sal farmaceuticamente aceitável e/ou um solvato do mesmo.
BR112015007870-2A 2012-10-11 2013-09-13 Composição compreendendo derivado de 6-oxo-1,6-di-hidro-piridazina e inibidor de mek, e seus usos BR112015007870B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12007039.6 2012-10-11
EP12007039 2012-10-11
PCT/EP2013/002747 WO2014056566A1 (en) 2012-10-11 2013-09-13 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor

Publications (2)

Publication Number Publication Date
BR112015007870A2 true BR112015007870A2 (pt) 2017-07-04
BR112015007870B1 BR112015007870B1 (pt) 2021-12-07

Family

ID=47048932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015007870-2A BR112015007870B1 (pt) 2012-10-11 2013-09-13 Composição compreendendo derivado de 6-oxo-1,6-di-hidro-piridazina e inibidor de mek, e seus usos

Country Status (17)

Country Link
US (1) US20150297594A1 (pt)
EP (1) EP2906294B1 (pt)
JP (1) JP2015536910A (pt)
KR (1) KR102157501B1 (pt)
CN (1) CN104703655A (pt)
AR (1) AR092991A1 (pt)
AU (1) AU2013329865B2 (pt)
BR (1) BR112015007870B1 (pt)
CA (1) CA2887628C (pt)
ES (1) ES2679372T3 (pt)
HK (1) HK1211255A1 (pt)
IL (1) IL238061B (pt)
MX (1) MX359110B (pt)
RU (1) RU2684407C2 (pt)
SG (1) SG11201502628SA (pt)
WO (1) WO2014056566A1 (pt)
ZA (1) ZA201503186B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170090498A (ko) * 2014-12-11 2017-08-07 메르크 파텐트 게엠베하 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 퀴나졸린 유도체의 조합
RU2017124612A (ru) * 2014-12-12 2019-01-14 Мерк Патент Гмбх Комбинация производного 6-оксо-1, 6-дигидро-пиридазона, обладающего противораковой активностью, с ингибитором рэфр
RS61126B1 (sr) * 2016-10-27 2020-12-31 Fujian Cosunter Pharmaceutical Co Ltd Jedinjenje piridona kao inhibitor c-met

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
AR084216A1 (es) * 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit

Also Published As

Publication number Publication date
CA2887628A1 (en) 2014-04-17
ES2679372T3 (es) 2018-08-24
US20150297594A1 (en) 2015-10-22
EP2906294A1 (en) 2015-08-19
CN104703655A (zh) 2015-06-10
RU2684407C2 (ru) 2019-04-09
EP2906294B1 (en) 2018-04-18
AR092991A1 (es) 2015-05-13
JP2015536910A (ja) 2015-12-24
AU2013329865A1 (en) 2015-05-21
ZA201503186B (en) 2021-09-29
WO2014056566A1 (en) 2014-04-17
CA2887628C (en) 2020-09-08
IL238061B (en) 2019-10-31
IL238061A0 (en) 2015-05-31
KR20150067343A (ko) 2015-06-17
SG11201502628SA (en) 2015-05-28
AU2013329865B2 (en) 2018-04-26
MX359110B (es) 2018-09-14
MX2015004428A (es) 2015-06-24
RU2015117550A (ru) 2016-12-10
KR102157501B1 (ko) 2020-09-18
HK1211255A1 (en) 2016-05-20
BR112015007870B1 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
SV2009002900A (es) Diarilurea para el tratamiento de hipertension pulmonar
PE20081751A1 (es) Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
JP2012136529A5 (pt)
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BR112013030939A2 (pt) derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo
EA201291167A1 (ru) Замещенные гетероциклилбензилпиразолы и их применение
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
BR112015007870A2 (pt) combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com um inibidor de mek
BR112017010232A2 (pt) Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um derivado de quinazolina
WO2010123956A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
BR112014009165A2 (pt) sal e uso médico
BR112015030171A2 (pt) composto, composição farmacêutica, método para prevenir ou tratar uma doença ou seus sintomas, uma afecção ou um distúrbio mediado parcial ou completamente por receptores nicotínicos de acetilcolina, uso de 4-(5-(4- clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il) benzenossulfonamida
BR112017012136A2 (pt) Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
PH12017501832A1 (en) Stabilized pharmaceutical composition
EA201001125A1 (ru) Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид
HRP20171295T1 (hr) Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc)
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
WO2011111066A3 (en) Composition and uses thereof
BR112022000266A2 (pt) Preparação farmacêutica
MY183976A (en) Pharmaceutical composition for oral administration with improved dissolution and/or absorption

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/09/2013, OBSERVADAS AS CONDICOES LEGAIS.